A New and Cost-Effective Tool to Combat the E-cigarette Epidemic Among Youth ACTON, MA, May 5, 2020 (GLOBE NEWSWIRE) — Psychemedics Corporation (NASDAQ: PMD), the world leader and pioneer in detecting drugs of abuse using hair analysis, today introduced a Vaping Panel to detect the use of Marijuana, CBD and Nicotine. This test provides a … Read more
A New and Cost-Effective Tool to Detect and Deter Nicotine use ACTON, MA, April 29, 2020 (GLOBE NEWSWIRE) — Psychemedics Corporation (NASDAQ: PMD), the world leader and pioneer in detecting drugs of abuse using hair analysis, today introduced the first FDA-cleared hair test for cotinine, the predominant metabolite for nicotine. This test provides a way … Read more
Industry’s first and only FDA-cleared Fentanyl screen available now ACTON, MA, April 24, 2019 (GLOBE NEWSWIRE) — Psychemedics Corporation (NASDAQ:PMD), the world leader and pioneer in detecting drugs of abuse using hair analysis, today introduced the industry’s first and only FDA-cleared hair test for Fentanyl, a major killer increasingly found in illegal drugs. According to … Read more
Acton, MA, April 23, 2019 — Psychemedics Corporation (NASDAQ:PMD) today announced first-quarter financial results for the period ended March 31, 2019. The Company also announced a quarterly dividend of $0.18 per share payable to shareholders of record as of May 7, 2019, to be paid on May 17, 2019. This will be the Company’s 91st … Read more
Industry’s first commercial application of hydroxycocaines for detection SAN ANTONIO, TX and ACTON, MA, March 27, 2019 (GLOBE NEWSWIRE) — Psychemedics Corporation (NASDAQ: PMD), the world leader in detecting drugs of abuse using hair analysis, today at the National Drug and Alcohol Screening Association (NDASA) Conference introduced the industry’s first confirmation process to accurately measure … Read more
In another first, the world’s largest hair drug testing company & scientific leader launches new test for Benzodiazepines Acton, Massachusetts, September 26, 2017 – Psychemedics Corporation (NASDAQ:PMD), hair testing pioneer and global leader for over thirty years, announced the launch of its FDA-Cleared Benzodiazepines hair test. The test detects numerous Benzodiazepines, including Xanax®, Valium®, and … Read more
World’s largest hair drug testing company & scientific leader launches new tool for combatting rising Synthetic Cannabinoids (K2, Spice) abuse Acton, Massachusetts, August 22, 2017– Psychemedics Corporation (NASDAQ:PMD), hair testing pioneer and global scientific leader for over thirty years, announced the launch of its Synthetic Cannabinoids test – a hair test that looks for the … Read more
Acton, MA, August 16, 2017 — Psychemedics Corporation (NASDAQ:PMD) today announced it has become the first laboratory to be approved for the testing of drugs of abuse in hair by the State of Iowa. On May 9, 2017, Governor Terry Branstad signed into law an Act allowing private sector pre-employment drug testing using hair samples. … Read more